☰

Joshua F. Heiber, Ph.D.

Affiliations: 
2011 Microbiology and Immunology (Medicine) University of Miami, Coral Gables, FL 
Area:
Virology Biology, Immunology
Google:
"Joshua Heiber"
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Glen N. Barber grad student 2011 University of Miami
 (Characterization and development of vesicular stomatitis virus for use as an oncolytic vector.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kurisetty VV, Heiber J, Myers R, et al. (2014) Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head & Neck. 36: 1619-27
Heiber JF, Barber GN. (2012) Evaluation of innate immune signaling pathways in transformed cells. Methods in Molecular Biology (Clifton, N.J.). 797: 217-38
Heiber JF, Xu XX, Barber GN. (2011) Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer. Chinese Journal of Cancer. 30: 805-14
Heiber JF, Barber GN. (2011) Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. Journal of Virology. 85: 10440-50
Elsby R, Heiber JF, Reid P, et al. (2011) The alpha subunit of eukaryotic initiation factor 2B (eIF2B) is required for eIF2-mediated translational suppression of vesicular stomatitis virus. Journal of Virology. 85: 9716-25
Kurisetty V, Heiber J, Perreira G, et al. (2011) Abstract 4313: Preclinical safety and efficacy of VSV-IFN-b in a syngeneic, immunocompetent model of head and neck squamous cell carcinoma Cancer Research. 71: 4313-4313
Gutman D, Heiber J, Elsby R, et al. (2011) PS2-074 Development of recombinant vesicular stomatitis virus for use as oncolytic vector Cytokine. 56: 84
Heiber JF, Ahn J, Barber GN. (2011) PS2-068 Vesicular stomatitis virus (VSV) expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent Cytokine. 56: 83
Capo-chichi CD, Yeasky TM, Heiber JF, et al. (2010) Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecologic Oncology. 116: 269-75
Heiber JF, Acevedo J, Gutman D, et al. (2010) SS5-7 Development of recombinant vesicular stomatitis virus that modulate immunity for use as an oncolytic vector Cytokine. 52: 45
See more...